Symbols / EFTR $0.00 +0.00% eFFECTOR Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
EFTR Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 2.35K
Enterprise Value -5.13M
Income -34.63M
Sales —
FCF (ttm) -17.67M
Book/sh 0.21
Cash/sh 5.40
Employees 14
Insider 10d —
IPO Aug 27, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S —
P/B 0.00
P/C —
EV/EBITDA 0.16
EV/Sales —
Quick Ratio 0.99
Current Ratio 1.03
Debt/Eq 2,448.37
LT Debt/Eq —
EPS (ttm) -12.57
EPS next Y -2.25
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-05-09
Earnings (prior) 2024-05-09
ROA -83.33%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 4.70M
Shs Float 4.67M
Insider Own 0.00%
Instit Own 0.00%
Short Float 1.97%
Short Ratio 0.97
Short Interest 91.62K
52W High 0.01
vs 52W High -95.00%
52W Low 0.00
vs 52W Low 150.00%
Beta 2.42
Impl. Vol. —
Rel Volume 0.71
Avg Volume 467.00
Volume 331.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-67.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-03-28 reit HC Wainwright & Co. Buy → Buy $24
2024-02-06 main HC Wainwright & Co. Buy → Buy $24
News
RSS: Latest EFTR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-05-15 BYRNES MICHAEL Chief Financial Officer — 1,387 $1.68 $2,334
2024-05-15 WORLAND STEPHEN T Chief Executive Officer — 1,806 $1.68 $3,039
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
33.84
+4.45%
32.40
+1.59%
31.90
Research And Development
22.92
-1.69%
23.31
+16.82%
19.96
Selling General And Administration
10.93
-13.59%
12.64
-5.44%
13.37
General And Administrative Expense
10.93
-13.59%
12.64
-5.44%
13.37
Other Gand A
10.93
-13.59%
12.64
-5.44%
13.37
Other Operating Expenses
—
-3.55
-148.46%
-1.43
Total Expenses
33.84
+4.45%
32.40
+1.59%
31.90
Operating Income
-33.84
-4.45%
-32.40
-1.59%
-31.90
Total Operating Income As Reported
-33.84
-4.45%
-32.40
-1.59%
-31.90
EBITDA
-32.78
-61.00%
-20.36
-215.78%
17.59
Normalized EBITDA
-32.79
-0.93%
-32.48
-5.36%
-30.83
Reconciled Depreciation
0.11
+109.43%
0.05
+120.83%
0.02
EBIT
-32.89
-61.12%
-20.41
-216.24%
17.56
Total Unusual Items
0.01
-99.95%
12.12
-74.96%
48.42
Total Unusual Items Excluding Goodwill
0.01
-99.95%
12.12
-74.96%
48.42
Special Income Charges
0.01
-99.95%
12.12
-74.96%
48.42
Other Special Charges
—
—
0.49
Restructuring And Mergern Acquisition
-0.01
+99.95%
-12.12
+75.21%
-48.91
Net Income
-35.81
-58.00%
-22.66
-243.47%
15.80
Pretax Income
-35.81
-58.00%
-22.66
-243.47%
15.80
Net Non Operating Interest Income Expense
-1.95
-7.45%
-1.81
-3.07%
-1.76
Interest Expense Non Operating
2.92
+29.68%
2.25
+27.61%
1.76
Net Interest Income
-1.95
-7.45%
-1.81
-3.07%
-1.76
Interest Expense
2.92
+29.68%
2.25
+27.61%
1.76
Interest Income Non Operating
0.97
+121.41%
0.44
+7216.67%
0.01
Interest Income
0.97
+121.41%
0.44
+7216.67%
0.01
Other Income Expense
-0.02
-100.17%
11.55
-76.64%
49.45
Other Non Operating Income Expenses
-0.03
+95.47%
-0.57
-155.46%
1.03
Tax Provision
—
—
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
13.07
Net Income Including Noncontrolling Interests
-35.81
-58.00%
-22.66
-243.47%
15.80
Net Income From Continuing Operation Net Minority Interest
-35.81
-58.00%
-22.66
-243.47%
15.80
Net Income From Continuing And Discontinued Operation
-35.81
-58.00%
-22.66
-243.47%
15.80
Net Income Continuous Operations
-35.81
-58.00%
-22.66
-243.47%
15.80
Normalized Income
-35.82
-2.95%
-34.79
-77.97%
-19.55
Net Income Common Stockholders
-35.81
-58.00%
-22.66
-243.47%
15.80
Otherunder Preferred Stock Dividend
—
—
0.00
Diluted EPS
-16.37
-19.05%
-13.75
-225.00%
11.00
Basic EPS
-16.37
-19.05%
-13.75
-152.38%
26.25
Basic Average Shares
2.19
+32.77%
1.65
+172.61%
0.60
Diluted Average Shares
2.19
+32.77%
1.65
+14.38%
1.44
Diluted NI Availto Com Stockholders
-35.81
-58.00%
-22.66
-243.47%
15.80
Average Dilution Earnings
—
—
0.00
Line Item Trend 2023-12-31 2021-12-31
Total Assets
20.54
-61.99%
54.06
Current Assets
19.84
-62.50%
52.90
Cash Cash Equivalents And Short Term Investments
18.37
-63.04%
49.70
Cash And Cash Equivalents
14.88
-70.07%
49.70
Cash Equivalents
—
49.70
Other Short Term Investments
3.50
0.00
Prepaid Assets
—
3.19
Other Current Assets
1.47
-54.04%
3.19
Total Non Current Assets
0.71
-39.14%
1.16
Net PPE
0.19
-24.90%
0.26
Gross PPE
0.52
+12.15%
0.46
Accumulated Depreciation
-0.32
-58.82%
-0.20
Properties
0.00
0.00
Machinery Furniture Equipment
0.23
+21.47%
0.19
Construction In Progress
0.01
-81.08%
0.07
Other Properties
0.08
-57.65%
0.20
Leases
0.19
0.00
Other Non Current Assets
0.51
-43.19%
0.90
Total Liabilities Net Minority Interest
26.34
-28.37%
36.77
Current Liabilities
25.80
+548.47%
3.98
Payables And Accrued Expenses
3.66
+41.41%
2.59
Payables
2.33
+168.74%
0.87
Accounts Payable
2.33
+351.55%
0.52
Current Accrued Expenses
1.33
-22.62%
1.72
Pensionand Other Post Retirement Benefit Plans Current
1.59
+18.17%
1.34
Total Tax Payable
—
0.35
Income Tax Payable
—
0.35
Current Debt And Capital Lease Obligation
20.55
+46593.18%
0.04
Current Debt
20.48
—
Other Current Borrowings
—
—
Current Capital Lease Obligation
0.06
+36.36%
0.04
Total Non Current Liabilities Net Minority Interest
0.54
-98.34%
32.79
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
19.99
Long Term Debt
—
19.86
Long Term Capital Lease Obligation
0.00
-100.00%
0.13
Other Non Current Liabilities
—
12.13
Preferred Securities Outside Stock Equity
—
0.00
Stockholders Equity
-5.79
-133.53%
17.28
Common Stock Equity
-5.79
-133.53%
17.28
Capital Stock
0.00
-100.00%
0.00
Common Stock
0.00
-100.00%
0.00
Preferred Stock
0.00
0.00
Share Issued
2.98
+84.62%
1.62
Ordinary Shares Number
2.98
+84.62%
1.62
Treasury Shares Number
0.01
-96.00%
0.30
Additional Paid In Capital
173.58
+25.62%
138.18
Retained Earnings
-179.38
-48.37%
-120.90
Gains Losses Not Affecting Retained Earnings
0.00
0.00
Other Equity Adjustments
—
—
Total Equity Gross Minority Interest
-5.79
-133.53%
17.28
Total Capitalization
-5.79
-115.60%
37.14
Working Capital
-5.96
-112.18%
48.92
Invested Capital
14.69
-60.45%
37.14
Total Debt
20.55
+2.57%
20.03
Net Debt
5.61
—
Capital Lease Obligations
0.06
-64.71%
0.17
Net Tangible Assets
-5.79
-133.53%
17.28
Tangible Book Value
-5.79
-133.53%
17.28
Derivative Product Liabilities
0.04
-94.10%
0.68
Interest Payable
0.22
+67.67%
0.13
Line Of Credit
20.48
—
Non Current Accrued Expenses
0.50
—
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-29.55
-14.10%
-25.90
-4.06%
-24.89
Cash Flow From Continuing Operating Activities
-29.55
-14.10%
-25.90
-4.06%
-24.89
Net Income From Continuing Operations
-35.81
-58.00%
-22.66
-243.47%
15.80
Depreciation Amortization Depletion
0.11
+109.43%
0.05
+120.83%
0.02
Depreciation
0.11
+109.43%
0.05
—
Depreciation And Amortization
0.11
+109.43%
0.05
+120.83%
0.02
Other Non Cash Items
0.35
+103.26%
-10.62
+78.14%
-48.59
Stock Based Compensation
4.59
-13.85%
5.33
-38.41%
8.66
Operating Gains Losses
-0.00
+99.53%
-0.64
-18.18%
-0.54
Gain Loss On Investment Securities
—
-0.64
+38.12%
-1.03
Change In Working Capital
1.69
-37.06%
2.68
+1224.79%
-0.24
Change In Prepaid Assets
0.59
-62.73%
1.57
+224.02%
-1.27
Change In Payables And Accrued Expense
0.91
+0.11%
0.91
-53.44%
1.95
Change In Accrued Expense
0.05
+200.00%
-0.05
-102.90%
1.79
Change In Payable
0.85
-10.75%
0.96
+518.06%
0.15
Change In Account Payable
0.85
-10.75%
0.96
+518.06%
0.15
Change In Other Working Capital
-0.00
-125.00%
0.00
+136.36%
-0.01
Change In Other Current Assets
0.19
+0.00%
0.19
+121.26%
-0.90
Investing Cash Flow
14.48
+181.10%
-17.86
-3261.06%
0.56
Cash Flow From Continuing Investing Activities
14.48
+181.10%
-17.86
-3261.06%
0.56
Net PPE Purchase And Sale
-0.10
+49.48%
-0.19
-133.98%
0.56
Purchase Of PPE
-0.10
+49.48%
-0.19
-357.14%
-0.04
Sale Of PPE
—
0.00
-100.00%
0.61
Capital Expenditure
-0.10
+49.48%
-0.19
-357.14%
-0.04
Net Investment Purchase And Sale
14.58
+182.53%
-17.67
0.00
Purchase Of Investment
-17.17
+67.25%
-52.42
0.00
Sale Of Investment
31.75
-8.63%
34.75
0.00
Financing Cash Flow
21.23
+667.92%
2.77
-95.30%
58.81
Cash Flow From Continuing Financing Activities
21.23
+667.92%
2.77
-95.30%
58.81
Net Issuance Payments Of Debt
—
0.00
-100.00%
5.89
Issuance Of Debt
—
0.00
-100.00%
19.84
Repayment Of Debt
—
0.00
+100.00%
-13.94
Long Term Debt Issuance
—
0.00
-100.00%
19.84
Long Term Debt Payments
—
0.00
+100.00%
-13.94
Net Long Term Debt Issuance
—
0.00
-100.00%
5.89
Net Common Stock Issuance
21.18
+656.59%
2.80
0.00
Proceeds From Stock Option Exercised
0.06
+1766.67%
0.00
-94.64%
0.06
Net Other Financing Charges
—
-0.04
-100.07%
52.86
Changes In Cash
6.17
+115.04%
-40.99
-218.87%
34.49
Beginning Cash Position
8.71
-82.48%
49.70
+226.64%
15.22
End Cash Position
14.88
+70.82%
8.71
-82.48%
49.70
Free Cash Flow
-29.65
-13.63%
-26.09
-4.66%
-24.93
Interest Paid Supplemental Data
2.53
+38.73%
1.82
+36.04%
1.34
Amortization Of Securities
-0.47
-1178.38%
-0.04
0.00
Common Stock Issuance
21.18
+656.59%
2.80
0.00
Issuance Of Capital Stock
21.18
+656.59%
2.80
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category